Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma

Experimental Dermatology

Volumn 21, Issue 3, 2012, Pages 189-194

  Nakamura Wakatsuki, Taeko ^a   Oyama, Noritaka ^a   Yamamoto, Toshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bleomycin; Latency associated peptide; Mouse model; Scleroderma; Transforming growth factor

Indexed keywords

BLEOMYCIN; COLLAGEN ALPHA1; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYPROLINE; LATENCY ASSOCIATED PEPTIDE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; MAST CELL; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; FEMALE; LATENT TGF-BETA BINDING PROTEINS; MICE; MICE, INBRED C3H; SCLERODERMA, SYSTEMIC; SCLEROSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84857782096     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2011.01419.x     Document Type: Article

References (35)

1. Yamamoto T. Eur J Dermatol 2009: 19: 14-24.
2. Yamamoto T. Int Arch Allergy Immunol 2006: 140: 345-356.
3. Hamaguchi Y. J Dermatol 2010: 37: 42-53.
4. Yamamoto T, Takagawa S, Katayama I et al. Clin Immunol 1999: 92: 6-13.
5. Lakos G, Takagawa S, Chen S J et al. Am J Pathol 2004: 165: 203-217.
6. Jinnin M. J Dermatol 2010: 37: 11-25.
7. Huang X R, Chung A C, Zhou L et al. J Am Soc Nephrol 2008: 19: 233-242.
8. Wang W, Huang X R, Li A G et al. J Am Soc Nephol 2005: 16: 1371-1383.
9. Denton C P, Merkel P A, Furst D E et al. Arthritis Rheum 2007: 56: 323-333.
10. Bottinger E P, Factor V M, Tsang M L et al. Proc Natl Acad Sci 1996: 93: 5877-5882.
11. Zhang Y, McCormick L L, Gilliam A C. J Invest Dermatol 2003: 121: 713-719.
12. Yamamoto T, Takagawa S, Katayama I et al. J Invest Dermatol 1999: 112: 456-462.
13. Dziadzio M, Smith R E, Abraham D J et al. Rheumatology 2005: 44: 1518-1524.
14. Oi M, Yamamoto T, Nishioka K. J Med Dent Sci 2004: 51: 7-17.
15. Akhmetshina A, Dees C, Pileckyte M et al. FASEB J 2008: 22: 2214-2222.
16. Kokot A, Sindrilaru A, Schiller M et al. Arthritis Rheum 2009: 60: 592-603.
17. Wu M, Melichian D S, Chang E et al. Am J Pathol 2009: 174: 519-533.
18. Terao M, Murota H, Kitaba S et al. Exp Dermatol 2010: 19: 38-43.
19. Kawakami T, Ihn H, Xu W et al. J Invest Dermatol 1998: 110: 47-51.
20. Asano Y. J Dermatol 2010: 37: 54-70.
21. Gandhi R, Anderson D E, Weiner H L. J Immunol 2007: 178: 4017-4021.
22. Ali N A, Gaughan A A, Orosz C G et al. PLoS ONE 2008: 3: e1914.
23. Yoshizaki A, Iwata Y, Komura K et al. Am J Pathol 2008: 172: 1650-1663.
24. Boswell S, Sharif S, Alisa A et al. Immunology 2011: 133: 278-287.
25. Mori T, Kawara S, Shinozaki M et al. J Cell Physiol 1999: 181: 153-159.
26. Abraham D. Rheumatology 2008: 47: v8-v9.
27. Takehara K. J Rheumatol 2003: 30: 755-759.
28. Young G D, Murphy-Ullrich J E. J Biol Chem 2004: 279: 38032-38039.
29. Hinz B. Curr Rheumatol Rep 2009: 11: 120-126.
30. Navi D, Saegusa J, Liu F T. Clin Rev Allergy Immunol 2007: 33: 144-155.
31. Hugle T, Hogan V, White K E et al. Arthritis Rheum 2011: 63: 795-799.
32. Yamamoto T. Arch Dermatol Res 2006: 297: 333-344.
33. Shiota N, Kakizoe E, Shimoura K et al. Br J Pharmacol 2005: 145: 424-431.
34. Walker M, Harley R, Leroy E C. J Rheumatol 1990: 17: 57-59.
35. Yamamoto T, Takagawa S, Nishioka K. Arch Dermatol Res 2001: 293: 532-536.